Consumer Discretionary · Wholesale-Drugs, Proprietaries & Druggists' Sundries · Nasdaq · CIK 1474167 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $0.18Day −6.26%Mkt cap $10M1Y −78.2%Off 52W high −86.2%Vol (1Y) 105.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 3,131 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest10.3% of sh out |
| Days to cover1.0d |
| 13F net flow (QoQ)+0.16% |
| Top-10 13F concentration96.9% |
| Next report (est.)2026-10-25 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$69.5M |
| Earnings (TTM)-$21.1M |
| ROE−89.1% |
| Net margin−29.3% |
| ROIC−53.0% |
| Debt / equity0.20× |
| Sales growth 3Y9.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−63.3% |
| 1Y−78.2% |
| 3Y−88.4% |
| 5Y−95.3% |
| 10Y−97.4% |
| Since incept. (ann.)−23.2% |
Total return through 2026-07-29 · series begins 2010-07-26. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)105.6% |
| Ann. volatility (3Y)104.0% |
| Sharpe (1Y)−0.77 |
| Sharpe (3Y)−0.18 |
| Max drawdown (1Y)−86.2% |
| Max drawdown (3Y)−90.9% |
| Beta (3Y vs SPY)1.78 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 390,500 | $123,867 | 0.77% | +16.7% |
| GEODE CAPITAL MANAGEMENT, LLC | 318,111 | $100,916 | 0.63% | +60.1% |
| BlackRock, Inc. | 267,797 | $84,945 | 0.53% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 140,007 | $44,382 | 0.28% | new |
| VANGUARD FIDUCIARY TRUST CO | 95,735 | $30,348 | 0.19% | new |
| HRT FINANCIAL LP | 67,280 | $21,000 | 0.13% | +162.2% |
| STATE STREET CORP | 45,243 | $14,351 | 0.09% | +0.0% |
| XTX Topco Ltd | 40,477 | $12,839 | 0.08% | −59.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-16 | −$0.06 | — | $17.9M | +30.7% |
| 2025-12-31 | 2026-04-15 | — | — | $19.7M | +38.5% |
| 2025-09-30 | 2025-11-14 | −$0.17 | — | $17.1M | +37.9% |
| 2025-06-30 | 2025-08-18 | −$0.10 | — | $14.7M | +11.7% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-25 is ESTIMATED from filing cadence (median gap 96d) — not company-confirmed.
Wholesale 91% · Nutraceuticals And Pharmaceuticals 7% · Pharmamanufacturing 3% · Other 0%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
